The pharmaceutical industry is experiencing a significant transformation as artificial intelligence (AI) tools move beyond experimental phases to deliver tangible…
Read More
Novartis Secures Dual Regulatory Milestones: European Approval for Rhapsido and WHO Prequalification for Coartem Baby
Novartis has achieved significant regulatory successes on two fronts, with its oral therapy Rhapsido (remibrutinib) receiving marketing authorisation from the…
Read More
Apotex Acquires Cumberland Pharmaceuticals’ Branded Drug Portfolio for $100 Million, Ushering in New Era for Both Companies
Canadian pharmaceutical giant Apotex has announced a significant strategic acquisition, agreeing to purchase Cumberland Pharmaceuticals’ entire portfolio of branded commercial…
Read More
Regeneron cuts White House pricing deal, offers new gene therapy for free – Pharmaceutical Technology
Regeneron Pharmaceuticals has entered into a significant drug pricing agreement with the White House, marking a pivotal moment in the…
Read More
Harnessing Site Performance for Superior Cardiometabolic Clinical Trial Outcomes
Clinical trials in the highly complex and rapidly evolving field of cardiometabolic disease face a critical juncture: their success or…
Read More
Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings – Pharmaceutical Technology
The European Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions on three promising new drug candidates,…
Read More
Biogen Secures Global Rights to TJ Biopharma’s Felzartamab in Landmark $850 Million Deal, Aiming to Disrupt Multiple Myeloma Treatment Landscape
Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…
Read More
New Qulipta Study Data Bolsters Case Against Restrictive European Reimbursement Policies
New clinical trial results presented by AbbVie are poised to significantly influence the landscape of migraine prevention in Europe, providing…
Read More
Biomarker Battles: Clinicians Champion Surrogate Endpoints Amidst Regulatory Caution
The complex interplay between clinical trial methodologies and regulatory approval pathways is currently being shaped by a vigorous debate surrounding…
Read More
Tavapadon Poised for Competitive Parkinson’s Disease Market Following Promising Tremor Data
AbbVie’s tavapadon, an investigational oral once-daily dopamine D1/D5 partial agonist, is nearing a potential regulatory submission, bolstered by new post-hoc…
Read MoreYOU MAY HAVE MISSED
